Overview

Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy

Status:
Completed
Trial end date:
2018-03-23
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to explore safety and tolerability of eteplirsen in participants with advanced stage Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping.
Phase:
Phase 2
Details
Lead Sponsor:
Sarepta Therapeutics
Sarepta Therapeutics, Inc.